State Street’s Structure Therapeutics GPCR Stock Holding History

State Street’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Sell	44,629 -2,952	-6%	-$131K	﹤0.01%	3277
2026 Q1	$2.29M	Sell	47,581 -643	-1%	-$44K	﹤0.01%	3260
2025 Q4	$3.35M	Buy	48,224 +2,207	+5%	+$90.1K	﹤0.01%	3150
2025 Q3	$1.29M	Buy	46,017 +12,558	+38%	+$250K	﹤0.01%	3452
2025 Q2	$694K	Buy	33,459 +22,719	+212%	+$500K	﹤0.01%	3557
2025 Q1	$186K	Buy	10,740 +213	+2%	+$5.22K	﹤0.01%	3847
2024 Q4	$285K	Sell	10,527 -1,768	-14%	-$62.7K	﹤0.01%	3767
2024 Q3	$540K	Buy	12,295 +2,611	+27%	+$101K	﹤0.01%	3583
2024 Q2	$380K	Sell	9,684 -3,007	-24%	-$123K	﹤0.01%	3624
2024 Q1	$544K	Sell	12,691 -1,245	-9%	-$52.5K	﹤0.01%	3624
2023 Q4	$568K	Sell	13,936 -524	-4%	-$30K	﹤0.01%	3616
2023 Q3	$729K	Buy	14,460 +3,000	+26%	+$96.7K	﹤0.01%	3597
2023 Q2	$476K	Buy	+11,460	New	+$321K	﹤0.01%	3699

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

State Street's GPCR Position: Q2 2026 in Review

State Street reduced its Structure Therapeutics (GPCR) stake by 6.2% in Q2 2026, selling an estimated $131K and leaving 44,629 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3277.

State Street first reported a position in GPCR in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.35M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

State Street held 44,629 shares of Structure Therapeutics worth $2.4M as of Q2 2026.
State Street sold 2,952 Structure Therapeutics shares in Q2 2026, an estimated $131K.
Structure Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3277 holding.
State Street first reported a position in Structure Therapeutics in Q2 2023 and has held it in 13 quarters since.
State Street's Structure Therapeutics position peaked at $3.35M in Q4 2025.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.